Hey there, bargain hunter. A 6% yield from a household-name drugmaker with a 10-forward P/E sounds like the kind of deal you circle in red. Before you do, run the actual numbers. Some of them look fine. Others look like a slow leak.
Scoreboard
Pfizer reports Q3 before the open on Tuesday, November 3. The Zacks consensus sits at $0.72 per share on $16.13 billion in revenue, both figures down year-over-year: EPS off about 17% from the $0.87 it posted in Q3 2025, revenue down roughly 3%. Full-year 2026 EPS estimates have been trimmed from $2.98 to $2.94 over the past 30 days. The bar is low. Pfizer has beaten consensus in each of its last eight quarters, so another beat is baked in by many desks. What is not baked in is what management says about the obesity pipeline on the call.
What Actually Happened
The Q2 miss that set up today’s anxiety was not really a miss: Pfizer posted $0.77 against a $0.68 consensus, a 13% upside surprise. The confusion comes from sequencing. The prior quarter’s beat reset expectations higher, and then a roughly $0.10 per-share impact tied to the Innovent Biologics transaction was flagged for full-year 2026 adjusted EPS. That one item explains most of the gap between where estimates sat 90 days ago and where they sit today.
COVID revenue keeps compressing. Paxlovid consensus for Q3 stands at $326 million. Comirnaty sits at $776 million. Those two lines combined used to deliver billions per quarter. Non-COVID drugs, including Ibrance at $1.03 billion and Padcev at $692 million, are picking up slack but not all of it.
The Obesity Question
The Metsera acquisition in late 2025 bought Pfizer back into the obesity race after danuglipron, its oral GLP-1 candidate, was discontinued in April 2025 following a potential drug-induced liver injury in one trial participant. That setback left the company with a narrowed pipeline and a credibility problem in the hottest therapeutic market on earth.
Correction: Pfizer described the Metsera deal as an enterprise value of approximately $4.9 billion at signing, plus contingent value rights that could raise the total value if milestones are met. Some coverage at the time framed the potential total value as “up to” about $10 billion.
Berobenatide, a key Metsera asset, showed 12.3% placebo-adjusted weight loss at 28 weeks in the Phase 2b VESPER-3 study, with the topline results reflecting an initial period of weekly dosing followed by monthly dosing. That monthly profile is the differentiator: Lilly’s Zepbound and Novo’s Wegovy require weekly injections. Pfizer has indicated Phase 3 plans for berobenatide, with a first potential approval targeted for 2028. Tuesday’s call will likely include an enrollment update. Listen for it.
The monthly-dosing differentiator matters only if Pfizer can close the efficacy gap with entrenched rivals. Novo Nordisk’s Wegovy franchise kept growing even as its stock fell nearly 30%, showing how durable a first-mover obesity brand can be.
Is It Cheap?
At roughly 10x to 11x forward earnings, Pfizer trades at a steep discount to many large-cap pharma peers. That is either a bargain or a warning, depending on whether you trust the earnings base. The dividend is the pressure point. At $1.72 per share annually, the yield sits near 5.7% to 6%. The payout ratio based on GAAP earnings can look extreme because GAAP has absorbed large non-cash charges in recent periods. On adjusted EPS, the dividend math looks more manageable. But in full-year 2025, free cash flow only narrowly covered the dividend, at about 108% of the payout. Pfizer was, in effect, leaving itself little room for error.
Free cash flow that barely covers a dividend also constrains how aggressively Pfizer can bid for pipeline assets. The patent cliff is forcing the largest acquisition wave in biopharma history, and companies with stretched balance sheets are arriving late to that auction.
Bull / Base / Bear
- Bull: Berobenatide hits Phase 3 efficacy targets, non-COVID drugs grow faster than patent-cliff losses, management raises full-year guidance Tuesday, and the dividend gets covered by recovering free cash flow by 2027.
- Base: Q3 beats the low bar, full-year guide holds around $2.94, obesity pipeline milestones stay on track but produce no near-term revenue. Stock stays range-bound around 10x earnings.
- Bear: A berobenatide Phase 3 safety signal, a further estimate cut, or a dividend reduction announcement collapses the income thesis and sends shares through the 52-week low. The company has already burned through danuglipron and at least one earlier GLP-1 program.
Action Plan
Do not buy ahead of the earnings release on yield alone. A 6% dividend that consumes about 100% of free cash flow is a yellow flag, not a green light. If Tuesday’s report shows non-COVID revenue growth above 5% and management reaffirms the full-year guide, a small starter position is defensible. Scale to full size only after a clean berobenatide Phase 3 update. Trim aggressively on any dividend language that hedges commitment.
Cheap Investor Scorecard
- Q3 EPS vs. $0.72 consensus: beat or miss?
- Revenue vs. $16.13 billion: coverage ratio on the dividend trending better?
- Full-year guide: held, raised, or cut?
- Berobenatide Phase 3 enrollment update: on schedule?
- Free cash flow trajectory: above or below $1.72 annualized dividend?
- Non-COVID drug growth rate: above 5% year-over-year?
- Paxlovid and Comirnaty decline rate: steeper than modeled?
- Management commentary on dividend sustainability: any hedging?
Bottom Line
If Pfizer beats Tuesday, holds the guide, and gives berobenatide a clean Phase 3 progress report, the 10x multiple starts to look like genuine value. If the guide comes down again or the obesity call disappoints, that yield is not income: it is a warning label. Watch the free cash flow language, not just the EPS number.
